BloodFlow is a technology company.
BloodFlow has raised $1.0M across 1 funding round.
BloodFlow has raised $1.0M in total across 1 funding round.
BloodFlow has raised $1.0M in total across 1 funding round.
BloodFlow's investors include ATP (Apple Tree Partners).
BloodFlow is a Lisbon-based healthtech startup that develops an AI-powered platform for analyzing routine blood test results, delivering immediate, actionable, medically accurate insights to clinicians via a plug-and-play API that integrates into hospital systems.[1][7] It serves healthcare providers such as hospitals and physicians, solving the problem of time-consuming manual review and transcription of blood diagnostics by automating interpretations with 98.3% accuracy, reducing review time by 95% on average, and enabling potential annual savings of up to €320,000 per clinical setting—having already processed over 50,000 patient reports.[1] The company recently secured €1.2 million in seed funding from 3xP Global’s Health Innovation Fund to fuel team expansion, market entry, regulatory certification, and applications like supporting pharmaceutical clinical trials.[1]
BloodFlow was founded by Tiago Cunha Costa, who serves as CEO, though specific details on his prior background are not detailed in available sources.[1] The idea emerged from a focus on specialized AI for blood test analysis, distinguishing it from general tools by prioritizing clinical precision and explainability for routine diagnostics.[1] Early traction includes analyzing over 50,000 patient reports with validated high accuracy by leading institutions, culminating in the €1.2M seed round in July 2025 from 3xP Global, a Lisbon-based PE firm emphasizing ESG principles—a pivotal moment enabling European scaling.[1]
(Note: A separate Canadian entity, BloodFlow Inc., focuses on mobile tech for blood donor engagement but appears distinct based on location, product, and founders.[2])
BloodFlow rides the wave of AI-driven precision medicine and healthtech automation, capitalizing on growing demand for efficient diagnostics amid clinician shortages and rising healthcare costs in Europe.[1][7] Timing aligns with post-pandemic emphasis on workflow optimization and ESG-aligned investments, as seen in backer 3xP Global's Iberian focus.[1] Favorable market forces include regulatory pushes for AI medical devices and pharma needs for trial data analysis, positioning BloodFlow to influence clinical standards by reducing diagnostic delays and errors across hospitals.[1]
BloodFlow is primed for accelerated growth with its recent funding, targeting new markets, team buildup, and medical device certification to solidify credibility.[1] Trends like AI regulatory approvals and personalized health insights will shape its path, potentially expanding to consumer-facing biomarker tracking.[7] Its influence may evolve from niche blood analysis to a key player in European healthtech ecosystems, driving broader adoption of explainable AI in diagnostics and enhancing patient outcomes at scale—transforming routine tests from burdens into strategic assets, as its funding milestone signals.[1]
BloodFlow has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $1.0M Seed | ATP (Apple Tree Partners) |